Given the capacity of GATA3 to catalyze cellular reprogramming relevant to cancer biology, characterization of the impact of cancer-specific mutations in this pioneering TF represents a field or enquiry with major clinical ramifications. This evidence concerns the gene GATA3 and cancer.